SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.

Andere talen Shenzhen Chipscreen Biosciences Co., Ltd.

Aandelen

688321

CNE100003LW0

slotkoers Shanghai S.E. Andere beurzen 00:00:00 26-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
18,88 ^CNY	+5,36%		-5,36%	-13,99%

30/04	National Medical Products Administration keurt Chidamide van Chipscreen Biosciences Co., Ltd. in combinatie met R-CHOP goed voor de behandeling van diffuus groot B-cellymfoom	CI
28/04	Shenzhen Chipscreen Biosciences Co, Ltd. Rapporteert winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Chipscreen Biosciences Gets China Nod for Phase 2 Trial of Pancreatic Cancer Drug	18/06
National Medical Products Administration Approves Chipscreen Biosciences Co., Ltd.'s Chidamide Combined with R-CHOP for the Treatment of Diffuse Large B-Cell Lymphoma	30/04
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	28/04
Chipscreen Biosciences Offers Sell-Back Option for Microchip Convertible Bond Holders	22/04
Tranche Update on Shenzhen Chipscreen Biosciences Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.	03/04
Shenzhen Chipscreen Biosciences Co., Ltd. commences an Equity Buyback Plan for CNY 15 million worth of its shares, under the authorization approved on February 22, 2024.	27/03
Shenzhen Chipscreen Biosciences Co., Ltd. Announces Positive Results from Phase II Clinical Trial (CGZ203 Study) of Chiglitazar Monotherapy for Non-Alalcoholic Steatohepatitis	18/03
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Chipscreen Biosciences' New Production Line Passes Regulatory Inspection	23/11
Chipscreen Biosciences Gets Regulatory Nod for China Clinical Trial of Psoriasis Drug	01/11
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30-10-23
Shenzhen Chipscreen Biosciences Co., Ltd.(XSSC:688321) added to S&P Global BMI Index	18-09-23
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	11-08-23
Chinese Drug Regulator to Prioritize Shenzhen Chipscreen Biosciences' Application for Chidamide Tablets	21-07-23
Shenzhen Chipscreen Biosciences Gets Nod for Tumor Drug Trial	27-06-23
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27-04-23
Biocytogen's Subsidiary Eucure Biopharma and Chipscreen Biosciences Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008	28-02-23
Biocytogens Tochtergesellschaft Eucure Biopharma und die Tochtergesellschaft der Holding Chipscreen Biosciences, Chipscreen NewWay Biosciences, schließen einen Lizenzvertrag für die Region China über den bispezifischen Antikörper YH008	27-02-23
Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008	27-02-23
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27-02-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Shenzhen Chipscreen Biosciences Co., Ltd.

Aandelen

688321

CNE100003LW0

Andere talen

Filters